Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
A vaccine is seen as the world’s best bet for taming a virus that has infected more than 48 million people, led to over 1.2 million deaths, roiled markets and disrupted countless lives because it was first identified in China in December. Australia is beefing up its potential arsenal against the pandemic to 135 million doses of various vaccine candidates.
“We are not putting all our eggs in one basket,” Prime Minister Scott Morrison said on Thursday.
Some 45 vaccine candidates are in human trials globally, with Pfizer Inc saying it might file in late November for U.S. authorisation, opening up the possibility of a vaccine being available in the United States at the end of the year.
Moderna and AstraZeneca are close behind the largest U.S. drugmaker and are likely to have early data on their vaccine candidates before the end of the year.
An Indian government-backed vaccine could be launched as early as February – weeks sooner than anticipated as last-stage trials begin this month and studies have shown it is safe and effective, a senior government scientist told Reuters.
Bharat Biotech, a private company that’s developing COVAXIN with the government-run Indian Council of Medical Research (ICMR), had earlier hoped to launch it just in the second quarter of next year.
“The vaccine has shown good efficacy,” senior ICMR scientist Rajni Kant, who is also a member of its COVID-19 task force, said at the research body’s New Delhi headquarters.
“It is anticipated that by the beginning of next year, February or March, something would be accessible.”
Bharat Biotech couldn’t immediately be reached.
A launch in February would make COVAXIN the first India-made vaccine to be rolled out.
AstraZeneca has signed multiple deals to supply over three billion doses of its candidate to nations around the world.
However a summer dip in British coronavirus infections had pushed back test results, causing the drugmaker to delay deliveries of shots into the government.
Britain’s vaccines chief said on Wednesday it would receive just 4 million doses of the possible vaccine this year, against initial estimates for 30 million by Sept. 30.
AstraZeneca said on Thursday it was holding back deliveries while it awaits the data from late-stage clinical trials in order to maximise the shelf-life of supplies.
